Tempest Therapeutics (TPST) Operating Income (2012 - 2026)
Tempest Therapeutics (TPST) posted Operating Income of -$4.1 million for Q4 2025, down 13.34% sequentially from -$3.6 million in Q3 2025, and up 70.71% YoY from -$2.4 million in Q4 2024.
Tempest Therapeutics (TPST) Operating Income (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Operating Income for 14 years, with the latest figure at -$4.1 million in Q4 2025.
- Quarterly Operating Income rose 70.71% year-over-year to -$4.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.6 million (up 36.76% YoY) and the FY2025 annual result came in at -$26.6 million, up 36.77% from the prior year.
- Operating Income slipped to -$4.1 million in Q4 2025 per TPST's latest filing, from -$3.6 million in the prior quarter.
- Over five years, Operating Income peaked at -$3.6 million in Q3 2025 and troughed at -$13.9 million in Q4 2024.
- A 5-year average of -$8.0 million and a median of -$7.9 million in 2021 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 78.59% in 2021, down 242.36% in 2021.
- Over 5 years, Operating Income stood at -$7.3 million in 2021, then decreased by 21.75% to -$8.9 million in 2022, then increased by 15.89% to -$7.5 million in 2023, then tumbled by 85.23% to -$13.9 million in 2024, then jumped by 70.71% to -$4.1 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered -$4.1 million, -$3.6 million, and -$8.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | -5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.25 Mn |
| Dec 31, 2025 | -4.08 Mn |
| Sep 30, 2025 | -3.60 Mn |
| Jun 30, 2025 | -7.97 Mn |
| Mar 31, 2025 | -10.94 Mn |
| Dec 31, 2024 | -13.92 Mn |
| Sep 30, 2024 | -10.55 Mn |
| Jun 30, 2024 | -9.58 Mn |
| Mar 31, 2024 | -7.97 Mn |
| Dec 31, 2023 | -7.51 Mn |
| Sep 30, 2023 | -6.59 Mn |
| Jun 30, 2023 | -7.47 Mn |
| Mar 31, 2023 | -7.58 Mn |
| Dec 31, 2022 | -8.93 Mn |
| Sep 30, 2022 | -8.77 Mn |
| Jun 30, 2022 | -8.77 Mn |
| Mar 31, 2022 | -8.16 Mn |
| Dec 31, 2021 | -7.34 Mn |
| Sep 30, 2021 | -7.74 Mn |
| Jun 30, 2021 | -6.79 Mn |